Agenus (AGEN +8%) is up on light volume in early trade on the heels of its announcement that the FDA has accepted its IND filing for immuno-oncology (I-O) candidate AGEN2373, triggering a $7.5M milestone payment from collaboration partner Gilead Sciences (GILD).
AGEN2373 is a fully human monoclonal antibody that inhibits (binds to) an immune checkpoint protein called CD137.
The companies established their partnership in December 2018 to develop five I-O therapies.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.